Date: 2013-09-25
Type of information: IPO
Company: Bind Therapeutics (USA - MA)
Investors:
Amount: $70,5 million
Funding type: IPO
Planned used:
Others: * On September 25, 2013, Bind Therapeutics announced the closing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, resulting in gross proceeds of $70,500,000 before underwriting discounts and commissions. The shares began trading on The NASDAQ Global Select Market under the ticker symbol "BIND" on September 20, 2013. * On September 19, 2013, Bind Therapeutics announced the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market on September 20, 2013. In addition, BIND has granted the underwriters a 30-day option to purchase up to an additional 705,000 shares of common stock at the same price to cover over-allotments, if any. The offering is expected to close on September 25, 2013, subject to customary closing conditions. Credit Suisse (USA) and Cowen and Company are acting as joint book-running managers for the offering. Stifel Nicolaus & Company, Incorporated and JMP Securities LLC are acting as co-managers. A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission on September 19, 2013.
Therapeutic area: Cancer - Oncology
